Ameriprise
GMAB icon

Ameriprise’s Genmab GMAB Stock Holding History

Ameriprise’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
60,207
-1,717
-3% -$45.6K ﹤0.01% 3181
2026
Q1 		$1.66M Buy
61,924
+434
+0.7% +$13K ﹤0.01% 3040
2025
Q4 		$1.89M Buy
61,490
+2,314
+4% +$72.1K ﹤0.01% 3029
2025
Q3 		$1.81M Buy
59,176
+2,462
+4% +$60K ﹤0.01% 3054
2025
Q2 		$1.17M Buy
+56,714
New +$1.16M ﹤0.01% 3194
2024
Q2 		– Sell
-6,996
Closed -$209K – 3898
2024
Q1 		$209K Buy
+6,996
New +$206K ﹤0.01% 3679
2023
Q4 		– Sell
-6,268
Closed -$221K – 3924
2023
Q3 		$221K Buy
6,268
+337
+6% +$12.8K ﹤0.01% 3675
2023
Q2 		$225K Buy
5,931
+601
+11% +$24K ﹤0.01% 3698
2023
Q1 		$201K Sell
5,330
-228
-4% -$8.76K ﹤0.01% 3728
2022
Q4 		$236K Buy
+5,558
New +$229K ﹤0.01% 3667
2022
Q2 		– Sell
-5,669
Closed -$205K – 3932
2022
Q1 		$205K Sell
5,669
-6,812
-55% -$234K ﹤0.01% 3753
2021
Q4 		$494K Buy
12,481
+6,623
+113% +$276K ﹤0.01% 3530
2021
Q3 		$255K Buy
5,858
+232
+4% +$10.4K ﹤0.01% 3637
2021
Q2 		$230K Sell
5,626
-1,417
-20% -$54.7K ﹤0.01% 3720
2021
Q1 		$232K Sell
7,043
-29,324
-81% -$1.1M ﹤0.01% 3672
2020
Q4 		$1.48M Buy
36,367
+2,810
+8% +$105K ﹤0.01% 2916
2020
Q3 		$1.23M Buy
33,557
+27,559
+459% +$996K ﹤0.01% 2882
2020
Q2 		$204K Sell
5,998
-36,071
-86% -$983K ﹤0.01% 3490
2020
Q1 		$891K Buy
42,069
+796
+2% +$17.7K ﹤0.01% 2871
2019
Q4 		$921K Buy
41,273
+421
+1% +$9.19K ﹤0.01% 3090
2019
Q3 		$827K Buy
+40,852
New +$805K ﹤0.01% 3097

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameriprise's GMAB Position: Q2 2026 in Review

Ameriprise reduced its Genmab (GMAB) stake by 2.8% in Q2 2026, selling an estimated $45.6K and leaving 60,207 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3181.

Ameriprise first reported a position in GMAB in Q3 2019 and has held it in 21 quarters since. The position peaked at $1.89M in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Ameriprise held 60,207 shares of Genmab worth $1.65M as of Q2 2026.
  • Ameriprise sold 1,717 Genmab shares in Q2 2026, an estimated $45.6K.
  • Genmab made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3181 holding.
  • Ameriprise first reported a position in Genmab in Q3 2019 and has held it in 21 quarters since.
  • Ameriprise's Genmab position peaked at $1.89M in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.